CYTOKINETICS, INCORPORATED Tax Withholding Paid on Stock Awards
CYTOKINETICS, INCORPORATED (CYTK) reported Tax Withholding Paid on Stock Awards of $2.33 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-06
- CYTOKINETICS, INCORPORATED payment, tax withholding, share-based payment arrangement for the quarter ending 2026-06-30 was $1.49M, a 189.11% increase year-over-year.
- CYTOKINETICS, INCORPORATED payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-31 was $841.00K, a 6369.23% increase year-over-year.
- CYTOKINETICS, INCORPORATED payment, tax withholding, share-based payment arrangement for the quarter ending 2025-12-31 was $1.22M, a 3.30% increase year-over-year.
- CYTOKINETICS, INCORPORATED payment, tax withholding, share-based payment arrangement for the quarter ending 2025-09-30 was $720.00K.
- CYTOKINETICS, INCORPORATED payment, tax withholding, share-based payment arrangement for fiscal 2025 was $2.47M, a 87.43% decline from fiscal 2024.
- CYTOKINETICS, INCORPORATED payment, tax withholding, share-based payment arrangement for fiscal 2024 was $19.63M, a 86.66% increase from fiscal 2023.
- CYTOKINETICS, INCORPORATED payment, tax withholding, share-based payment arrangement for fiscal 2023 was $10.52M, a 9.53% increase from fiscal 2022.
- CYTOKINETICS, INCORPORATED payment, tax withholding, share-based payment arrangement for fiscal 2022 was $9.60M, a 115.82% increase from fiscal 2021.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.33M 10-Q · filed 2026-08-06 | $3.55M derived: sum of 3 quarters · filed 2026-08-06 | $4.27M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $841.00K 10-Q · filed 2026-05-05 | $2.06M derived: sum of 2 quarters · filed 2026-05-05 | $2.78M derived: sum of 3 quarters · filed 2026-05-05 | $3.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.94M derived: sum of 2 quarters · filed 2026-02-26 | $2.46M derived: sum of 3 quarters · filed 2026-08-06 | $2.47M 10-K · filed 2026-02-26 |
| 2025-09-30 | $720.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.23M derived: sum of 2 quarters · filed 2026-08-06 | $1.25M 10-Q · filed 2025-11-05 | $2.43M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $514.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $527.00K 10-Q · filed 2026-08-06 | $1.71M derived: sum of 3 quarters · filed 2026-08-06 | $1.71M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $13.00K 10-Q · filed 2026-05-05 | $1.20M derived: sum of 2 quarters · filed 2026-05-05 | $1.20M derived: sum of 3 quarters · filed 2026-05-05 | $1.20M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.18M derived: sum of 2 quarters · filed 2026-02-26 | $1.18M derived: sum of 3 quarters · filed 2026-02-26 | $19.63M 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $18.45M 10-Q · filed 2025-11-05 | $18.45M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $18.45M 10-Q · filed 2025-08-07 | $18.45M derived: sum of 3 quarters · filed 2026-02-26 | $18.45M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $18.45M 10-Q · filed 2025-05-06 | $18.45M derived: sum of 2 quarters · filed 2026-02-26 | $18.45M derived: sum of 3 quarters · filed 2026-02-26 | $18.45M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $10.52M 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $10.52M 10-Q · filed 2024-11-07 | $10.52M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $10.52M 10-Q · filed 2024-08-09 | $10.52M derived: sum of 3 quarters · filed 2025-02-27 | $10.52M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $10.52M 10-Q · filed 2024-05-10 | $10.52M derived: sum of 2 quarters · filed 2025-02-27 | $10.52M derived: sum of 3 quarters · filed 2025-02-27 | $10.52M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $0.00 derived: sum of 3 quarters · filed 2025-02-27 | $9.60M 10-K · filed 2025-02-27 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $0.00 derived: sum of 2 quarters · filed 2023-11-03 | $9.60M 10-Q · filed 2023-11-03 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $9.60M 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | $9.60M 10-Q · filed 2023-05-05 | |||
| 2021-12-31 | $4.45M 10-K · filed 2024-02-28 | |||
| 2020-12-31 | $2.25M 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |